Contributions
Abstract: EP1380
Type: ePoster
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Spastic paretic hemifacial contracture (SPHC) is an uncommon condition characterized by sustained unilateral contraction of the facial muscles associated with mild ipsilateral facial paresis. SPHC has been rarely described in the context multiple sclerosis (MS). We previously screened 500 consecutive MS patients and identified the condition in two cases during the course of an MS relapse. SPHC has never been reported to date as the presenting symptom of MS.
Case reports: We describe two patients who developed SPHC within the context of a clinically isolated syndrome (CIS) suggestive of MS. In both cases SPHC was the presenting symptom of the disease. It was characterized on electromyography (EMG) by continuous resting activity of irregularly firing motor unit potentials, associated with impaired recruitment of motor units on voluntary contraction. In one of the patients, brain MRI identified a contrast-enhancing lesion in the ipsilateral dorsolateral midpontine tegmentum. Both patients fulfilled Barkhof criteria for dissemination in space. SPHC remitted fully following high-dose intravenous steroid therapy.
Conclusions: SPHC, which constitutes a rare but distinct clinical and EMG entity in patients with MS, can very rarely be the presenting feature of the disease.
Disclosure:
G. Koutsis has received research grants from Genesis Pharma and Teva, consultation fees, advisory boards and honoraria from Genzyme, Genesis Pharma, Teva and Novartis.
M.E. Evangelopoulos has provided consultation services for and received honoraria from Novartis, Biogen and Teva.
M. Breza reports no conflict of interest.
C. Kilidireas received research grants from Biogen, Novartis, Teva, and Merck-Serono.
M. Anagnostouli received research grants from Biogen, Merck-Serono, Novartis, Teva, Bayer and Genzyme as well as lecture-fees from Novartis, Teva, Biogen and Genzyme.
E. Andreadou received research grants from Biogen, Merck-Serono, Novartis, and Sanofi Aventis as well as lecture-fees from Teva.
G. Karagiorgis reports no conflict of interest.
N. Karandreas reports no conflict of interest.
Abstract: EP1380
Type: ePoster
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Spastic paretic hemifacial contracture (SPHC) is an uncommon condition characterized by sustained unilateral contraction of the facial muscles associated with mild ipsilateral facial paresis. SPHC has been rarely described in the context multiple sclerosis (MS). We previously screened 500 consecutive MS patients and identified the condition in two cases during the course of an MS relapse. SPHC has never been reported to date as the presenting symptom of MS.
Case reports: We describe two patients who developed SPHC within the context of a clinically isolated syndrome (CIS) suggestive of MS. In both cases SPHC was the presenting symptom of the disease. It was characterized on electromyography (EMG) by continuous resting activity of irregularly firing motor unit potentials, associated with impaired recruitment of motor units on voluntary contraction. In one of the patients, brain MRI identified a contrast-enhancing lesion in the ipsilateral dorsolateral midpontine tegmentum. Both patients fulfilled Barkhof criteria for dissemination in space. SPHC remitted fully following high-dose intravenous steroid therapy.
Conclusions: SPHC, which constitutes a rare but distinct clinical and EMG entity in patients with MS, can very rarely be the presenting feature of the disease.
Disclosure:
G. Koutsis has received research grants from Genesis Pharma and Teva, consultation fees, advisory boards and honoraria from Genzyme, Genesis Pharma, Teva and Novartis.
M.E. Evangelopoulos has provided consultation services for and received honoraria from Novartis, Biogen and Teva.
M. Breza reports no conflict of interest.
C. Kilidireas received research grants from Biogen, Novartis, Teva, and Merck-Serono.
M. Anagnostouli received research grants from Biogen, Merck-Serono, Novartis, Teva, Bayer and Genzyme as well as lecture-fees from Novartis, Teva, Biogen and Genzyme.
E. Andreadou received research grants from Biogen, Merck-Serono, Novartis, and Sanofi Aventis as well as lecture-fees from Teva.
G. Karagiorgis reports no conflict of interest.
N. Karandreas reports no conflict of interest.